Cite
HARVARD Citation
Tirunagaru, V. et al. (n.d.). Combination of MDM2 inhibition with milademetan and MEK inhibition leads to improved anti-tumor activity in cancer models harboring WT TP53. European journal of cancer. pp. S20-S21. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Tirunagaru, V. et al. (n.d.). Combination of MDM2 inhibition with milademetan and MEK inhibition leads to improved anti-tumor activity in cancer models harboring WT TP53. European journal of cancer. pp. S20-S21. [Online].